Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis). Novo Nordisk Canada Inc ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies. Compare side effects here.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration ... loss of 5% or more.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...

accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that ... compared to 17.5% with the lower dose and 2.4% in the placebo group.

President Trump cast himself on the campaign trail as the savior of U.S. oil and gas. His shock treatment of the American economy has left the industry reeling. Since Trump took office, oil ...